OBJECTIVE: To estimate the effects of chlorhexidine vaginal and baby wipes on fetal and neonatal mortality, respectively, and infection-related morbidity. METHODS: We performed a placebo-controlled, randomized trial of chlorhexidine vaginal and neonatal wipes to reduce neonatal sepsis and mortality in three hospitals in Pakistan. The primary study outcome was a composite of neonatal sepsis or 7-day perinatal mortality. RESULTS:From 2005 to 2008, 5,008 laboring women and their neonates were randomly assigned to receive either chlorhexidine wipes (n=2,505) or wipes with a saline placebo (n=2,503). The primary outcome was similar in the chlorhexidine and control groups (3.1% compared with 3.4%; relative risk 0.91, 95% confidence interval 0.67-1.24) as was the composite rate of neonatal sepsis or 28-day perinatal mortality (3.8% compared with 3.9%, relative risk 0.96, 95% confidence interval 0.73-1.27). At day 7, the chlorhexidine group had a lower rate of neonatal skin infection (3.3% compared with 8.2%, P<.001). With the exception of less frequent 7-day hospitalization in the chlorhexidine group, there were no significant differences in maternal outcomes between the groups. CONCLUSION: Using maternal chlorhexidine vaginal wipes during labor and neonatal chlorhexidine wipes does not reduce maternal and perinatal mortality or neonatal sepsis. The finding of reduced superficial skin infections on day 7 without change in sepsis or mortality suggests that this difference, although statistically significant, may not be of major importance. LEVEL OF EVIDENCE: I.
RCT Entities:
OBJECTIVE: To estimate the effects of chlorhexidine vaginal and baby wipes on fetal and neonatal mortality, respectively, and infection-related morbidity. METHODS: We performed a placebo-controlled, randomized trial of chlorhexidine vaginal and neonatal wipes to reduce neonatal sepsis and mortality in three hospitals in Pakistan. The primary study outcome was a composite of neonatal sepsis or 7-day perinatal mortality. RESULTS: From 2005 to 2008, 5,008 laboring women and their neonates were randomly assigned to receive either chlorhexidine wipes (n=2,505) or wipes with a saline placebo (n=2,503). The primary outcome was similar in the chlorhexidine and control groups (3.1% compared with 3.4%; relative risk 0.91, 95% confidence interval 0.67-1.24) as was the composite rate of neonatal sepsis or 28-day perinatal mortality (3.8% compared with 3.9%, relative risk 0.96, 95% confidence interval 0.73-1.27). At day 7, the chlorhexidine group had a lower rate of neonatal skin infection (3.3% compared with 8.2%, P<.001). With the exception of less frequent 7-day hospitalization in the chlorhexidine group, there were no significant differences in maternal outcomes between the groups. CONCLUSION: Using maternal chlorhexidine vaginal wipes during labor and neonatal chlorhexidine wipes does not reduce maternal and perinatal mortality or neonatal sepsis. The finding of reduced superficial skin infections on day 7 without change in sepsis or mortality suggests that this difference, although statistically significant, may not be of major importance. LEVEL OF EVIDENCE: I.
Authors: Abhay T Bang; Rani A Bang; Barbara J Stoll; Sanjay B Baitule; Hanimi M Reddy; Mahesh D Deshmukh Journal: J Perinatol Date: 2005-03 Impact factor: 2.521
Authors: Craig M Wilson; Glenda Gray; Jennifer S Read; Anthony Mwatha; Sanjay Lala; Saul Johnson; Avye Violari; Portia Mabali Sibiya; Thomas R Fleming; Ann Koonce; Sten H Vermund; James McIntyre Journal: J Acquir Immune Defic Syndr Date: 2004-02-01 Impact factor: 3.731
Authors: Clare L Cutland; Shabir A Madhi; Elizabeth R Zell; Locadiah Kuwanda; Martin Laque; Michelle Groome; Rachel Gorwitz; Michael C Thigpen; Roopal Patel; Sithembiso C Velaphi; Peter Adrian; Keith Klugman; Anne Schuchat; Stephanie J Schrag Journal: Lancet Date: 2009-10-19 Impact factor: 79.321
Authors: E M McClure; R L Goldenberg; N Brandes; G L Darmstadt; L L Wright; Deborah Armbruster; Robert Biggar; Joyce Carpenter; Michael J Free; Donald Mattison; Matthews Mathai; Nancy Moss; Luke C Mullany; Stephanie Schrag; James Tielsch; Jorge Tolosa; Stephen N Wall; Anne Schuchat; Abdelkrim Smine Journal: Int J Gynaecol Obstet Date: 2007-03-30 Impact factor: 3.561
Authors: Luke C Mullany; Gary L Darmstadt; Joanne Katz; Subarna K Khatry; Steven C Leclerq; Ramesh K Adhikari; James M Tielsch Journal: Pediatr Infect Dis J Date: 2009-01 Impact factor: 2.129
Authors: Courtney A Gravett; Michael G Gravett; Emily T Martin; Jeffrey D Bernson; Sadaf Khan; David S Boyle; Sophia M R Lannon; Janna Patterson; Craig E Rubens; Matthew S Steele Journal: PLoS Med Date: 2012-10-09 Impact factor: 11.069
Authors: Hannah Blencowe; Simon Cousens; Luke C Mullany; Anne C C Lee; Kate Kerber; Steve Wall; Gary L Darmstadt; Joy E Lawn Journal: BMC Public Health Date: 2011-04-13 Impact factor: 3.295
Authors: Maryse C Kok; Marjolein Dieleman; Miriam Taegtmeyer; Jacqueline E W Broerse; Sumit S Kane; Hermen Ormel; Mandy M Tijm; Korrie A M de Koning Journal: Health Policy Plan Date: 2014-12-11 Impact factor: 3.344
Authors: Maryse C Kok; Sumit S Kane; Olivia Tulloch; Hermen Ormel; Sally Theobald; Marjolein Dieleman; Miriam Taegtmeyer; Jacqueline E W Broerse; Korrie A M de Koning Journal: Health Res Policy Syst Date: 2015-03-07
Authors: Aamer Imdad; Resti Ma M Bautista; Kathlynne Anne A Senen; Ma Esterlita V Uy; Jacinto Blas Mantaring; Zulfiqar A Bhutta Journal: Cochrane Database Syst Rev Date: 2013-05-31